Mangoceuticals, Competitors

Stocks . USA . 
Stock . Mangoceuticals, Common Stock
MGRX Stock   2.48  0.14  5.34%   
Mangoceuticals, Common competes with FOXO Technologies, Healthcare Triangle, Bullfrog, and EUDA Health; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Mangoceuticals, Common competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Mangoceuticals, Common to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Mangoceuticals, Common Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Mangoceuticals, Common competition on your existing holdings.
  
Return On Tangible Assets is likely to rise to -8.33 in 2024. Return On Capital Employed is likely to rise to -10.43 in 2024. At this time, Mangoceuticals, Common's Net Tangible Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to rise to 3.57 in 2024, whereas Total Assets are likely to drop slightly above 761.4 K in 2024.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.132.528.52
Details
Intrinsic
Valuation
LowRealHigh
0.122.468.46
Details

Mangoceuticals, Common Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mangoceuticals, Common and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Mangoceuticals, and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mangoceuticals, Common does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
AUGX
+ 0.66
AKLI
SNCE
+ 0.64
ETAO
HCTI
+ 0.59
FOXO
EUDA
+ 0.41
HCTI
AKLI
+ 0.4
HCTI
AKLI
+ 0.37
FOXO
  
High negative correlations   
AKLI
- 0.93
ETAO
AUGX
- 0.76
ETAO
AUGX
- 0.62
SNCE
SNCE
- 0.58
HCTI
AKLI
- 0.49
SNCE
HCTI
- 0.48
ETAO

Risk-Adjusted Indicators

There is a big difference between Mangoceuticals, Stock performing well and Mangoceuticals, Common Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mangoceuticals, Common's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
FOXO  16.69  1.51  0.43  0.16  9.48 
(36.70)
 34.29 
(10.00)
 509.71 
ETAO  16.91 (0.92) 0.00  0.76  0.00 
 0.00 
 58.10 
(42.00)
 247.80 
HCTI  7.89  1.80  0.16 (8.42) 8.74 
(10.75)
 10.34 
(18.35)
 131.09 
SNCE  5.28 (0.33) 0.00 (0.02) 0.00 
 0.00 
 11.11 
(10.00)
 29.72 
BFRG  3.59 (0.34) 0.00 (0.03) 0.00 
 0.00 
 6.72 
(7.45)
 41.78 
EUDA  4.66  0.05  0.00  0.21  6.79 
(4.52)
 9.70 
(10.50)
 26.33 
UTRS  6.67  0.75  0.07  10.17  6.57 
(13.00)
 14.81 
(13.04)
 107.58 
ACONW  5.93  1.04  0.07 (0.34) 6.53 
(13.80)
 27.09 
(15.28)
 58.58 
AKLI  3.90  1.13  0.16 (0.56) 3.07 
(7.72)
 5.13 
(7.14)
 78.36 
AUGX  4.50  2.04  0.86  1.27  0.00 
(7.39)
 2.25 
(1.09)
 146.54 

Cross Equities Net Income Analysis

Compare Mangoceuticals, Common and related stocks such as FOXO Technologies, Etao International Co,, and Healthcare Triangle Net Income Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
FOXO(8.6 M)(8.6 M)(8.6 M)(8.6 M)(8.6 M)(8.6 M)(8.6 M)(8.6 M)(8.6 M)(8.6 M)(8.6 M)(40 M)(148.9 M)(26.5 M)(27.8 M)
HCTI(5.8 M)(5.8 M)(5.8 M)(5.8 M)(5.8 M)(6.7 M)(4.6 M)1.2 M1.2 M1.2 M2.4 M(6 M)(9.6 M)(12.3 M)(11.7 M)
BFRG(341.7 K)(341.7 K)(341.7 K)(341.7 K)(341.7 K)(341.7 K)(341.7 K)(341.7 K)(341.7 K)(341.7 K)(341.7 K)(585.8 K)(2.8 M)(5.4 M)(5.1 M)
EUDA175.6 K175.6 K175.6 K175.6 K175.6 K175.6 K175.6 K175.6 K175.6 K175.6 K175.6 K864.8 K(24.9 M)(10 M)(10.5 M)
ACONW(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4 M)(4.8 M)(3.5 M)(9.1 M)(4.9 M)(5.2 M)

Mangoceuticals, Common and related stocks such as FOXO Technologies, Etao International Co,, and Healthcare Triangle Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Mangoceuticals, Common financial statement analysis. It represents the amount of money remaining after all of Mangoceuticals, Common Stock operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Mangoceuticals, Common Competitive Analysis

The better you understand Mangoceuticals, Common competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mangoceuticals, Common's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mangoceuticals, Common's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
MGRX FOXO ETAO HCTI SNCE BFRG EUDA UTRS ACONW AKLI
 5.34 
 2.48 
Mangoceuticals,
 35.90 
 0.53 
FOXO
 0.00 
 0.05 
Etao
 6.74 
 0.83 
Healthcare
 7.69 
 0.28 
Science
 4.05 
 2.13 
Bullfrog
 1.62 
 4.39 
EUDA
 0.00 
 0.26 
Minerva
 0.00 
 0.03 
Aclarion
 0.00 
 0.43 
Akili
Market Volatility
(90 Days Market Risk)
Dangerous
Out of control
Very steady
Out of control
Very steady
Dangerous
Very risky
Very steady
Out of control
Very steady
Market Performance
(90 Days Performance)
Very Weak
OK
Very Weak
Modest
Very Weak
Very Weak
Weak
Very Weak
Good
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Very High
About Average
Dangerous
Average
Dangerous
Low
Very High
Dangerous
Quite High
Dangerous
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Strong Sell
Not Available
Not Available
Strong Buy
Not Available
Strong Sell
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Not Rated
Strong Sell
Not Rated
Cautious Hold
Strong Sell
Not Rated
Strong Sell
Not Rated
Current Ratio
N/A
0.31
N/A
1.42
6.32
N/A
N/A
2.4
0.1
4.78
Net Asset
1.05 M
725 K
52.99 M
10.05 M
126.45 M
2.78 M
1.31 M
68.9 M
2.46 M
80.38 M
Profit Margin
N/A
N/A
N/A
-0.49
-2.07
N/A
N/A
-0.65
N/A
N/A
EBITDA
(9.19 M)
(24.25 M)
(734.58 M)
(4.1 M)
(59.86 M)
(5.28 M)
(8.3 M)
(30.88 M)
(4.14 M)
(60.14 M)
Operating Margin
-13.05
-56.75
-0.79
-0.46
-0.6
-96.73
-0.83
-0.51
-103.51
-28.37
Current Valuation
6.71 M
42.39 M
10.86 M
6.1 M
(21.22 M)
15.28 M
162.97 M
42.81 M
N/A
(15.56 M)
Price To Book
0.49
0.91
N/A
0.87
0.67
5.06
N/A
0.51
N/A
0.35
Retained Earnings
(11.23 M)
(177.06 M)
(907.54 M)
(24.91 M)
(253.07 M)
(9.75 M)
(34.74 M)
(283.67 M)
(44.28 M)
(299.78 M)
Current Asset
N/A
N/A
N/A
30 K
N/A
N/A
N/A
N/A
N/A
N/A
Beta
N/A
2.06
1.92
0.49
0.56
N/A
-0.004
0.83
0.4
1.73
Number Of Employees
3
N/A
3.6 K
22
460
N/A
106
174
4
68
Shares Outstanding
2.49 M
17.48 M
5.12 M
5.67 M
6.03 M
8.71 M
37.15 M
8.88 M
N/A
78.73 M
Cash Flow From Operations
(7 M)
(6.64 M)
10.82 M
(1.61 M)
(48.19 M)
(6 M)
(2.92 M)
(35.57 M)
(3.65 M)
(57.87 M)
Total Debt
128.68 K
4.2 M
15.41 M
4.32 M
1.32 M
184.35 K
3.37 M
39.69 M
1.13 M
15.48 M
Return On Equity
-1.08
-17.55
-11.61
-2.88
-1.19
-1.18
N/A
-1.6
-7.14
-0.68
Z Score
N/A
N/A
N/A
N/A
12.82
N/A
N/A
-5.93
N/A
N/A
Return On Asset
-0.58
-1.14
-4.15
-0.55
-0.28
-0.65
-0.86
-0.27
-1.15
-0.37
Number Of Shares Shorted
194.4 K
53.71 K
52.04 K
632.84 K
13.83 K
255.31 K
5.04 K
37.42 K
N/A
271.35 K
Book Value Per Share
0.54
-1.84
0.3
0.13
8.69
0.43
-0.17
2.28
-0.88
0.64
Current Liabilities
N/A
N/A
N/A
10.13 M
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
1.05 M
725 K
52.99 M
10.05 M
126.45 M
2.78 M
1.31 M
68.9 M
2.46 M
80.38 M
Short Ratio
0.21
0.24
0.05
0.09
0.22
2.3
0.09
0.51
N/A
0.31
Debt To Equity
N/A
N/A
N/A
0.23
0.005
N/A
N/A
1.3
N/A
0.79
Target Price
N/A
N/A
N/A
1.5
13.83
N/A
6.0
3.0
N/A
0.65
Shares Owned By Institutions
4.69
2.25
0.3
3.27
52.18
3.48
2.47
89.86
N/A
61.47
Market Capitalization
6.51 M
6.74 M
9.78 M
5.04 M
34.66 M
19.34 M
160.59 M
13.14 M
N/A
34.1 M
Price To Sales
7.52
43.51
0.35
0.23
0.58
297.59
42.13
0.25
N/A
12.31
Net Income
(9.21 M)
(26.45 M)
(897 M)
(12.34 M)
(124.65 M)
(5.36 M)
(8.43 M)
(34.11 M)
(4.91 M)
(59.49 M)
Earnings Per Share
-5.7
0.05
-175.64
-2.17
-21.4
-0.84
-0.62
-7.61
-6.58
-0.61
Shares Owned By Insiders
37.45
11.99
55.09
45.93
16.89
29.2
49.35
0.43
N/A
23.21
Revenue
731.49 K
145 K
58.06 M
33.2 M
60.26 M
65 K
3.71 M
50.29 M
75.4 K
1.68 M
Working Capital
607.38 K
(14.1 M)
(8.01 M)
(2.39 M)
103.03 M
2.59 M
(7.99 M)
21.84 M
(1.9 M)
65.06 M
Cash And Equivalents
N/A
18.5 M
N/A
1.36 M
130.24 M
N/A
N/A
22.39 M
452.53 K
45.62 M
Cash Per Share
N/A
5.22
N/A
0.04
1.12
N/A
N/A
0.78
0.5
0.53
Gross Profit
4.85 K
120 K
19 M
10.52 M
20.07 M
N/A
3.35 M
27.24 M
N/A
(118 K)
Day Typical Price
2.52
0.57
0.05
0.86
0.27
2.18
4.46
0.26
0.028
0.43
Accumulation Distribution
3490.96
58.9 M
N/A
5300.22
0.14
11531.97
8299.51
0.037
N/A
N/A
Market Facilitation Index
0.0
N/A
N/A
0.0
0.04
0.0
0.0
0.01
N/A
N/A
Daily Balance Of Power
(0.74)
0.4242
0.0
(0.67)
0.5
(0.36)
0.1842
N/A
0.0
0.0
Period Momentum Indicator
(0.14)
0.14
N/A
(0.06)
0.02
(0.09)
0.07
N/A
N/A
N/A
Rate Of Daily Change
0.95
1.36
1.0
0.93
1.08
0.96
1.02
1.0
1.0
1.0
Day Median Price
2.55
0.59
0.05
0.88
0.26
2.21
4.49
0.27
0.028
0.43
Price Action Indicator
(0.14)
0.015
N/A
(0.07)
0.03
(0.12)
(0.07)
(0.01)
N/A
N/A
Coefficient Of Variation
(1,219)
898.55
(3,159)
1005.02
(24,199)
(9,183)
5042.17
1767.12
1312.09
1039.66
Mean Deviation
4.35
16.69
16.91
7.89
5.28
3.59
4.66
6.67
5.93
3.9
Jensen Alpha
(0.53)
1.51
(0.92)
1.8
(0.33)
(0.34)
0.05
0.7508
1.04
1.13
Total Risk Alpha
(1.47)
(2.54)
(6.37)
(1.01)
(1.08)
(0.97)
(0.85)
(1.35)
(0.82)
(0.59)
Sortino Ratio
N/A
0.4315
N/A
0.1591
N/A
N/A
(0.0008)
0.0691
0.0682
0.1624
Downside Variance
N/A
212.32
N/A
108.69
N/A
N/A
49.51
86.05
92.32
25.11
Standard Deviation
6.17
57.65
34.05
17.96
6.69
5.81
6.2
13.6
10.28
9.8
Kurtosis
4.86
59.91
12.18
34.02
0.2747
14.32
1.15
22.1
3.08
48.89
Potential Upside
7.29
34.29
58.1
10.34
11.11
6.72
9.7
14.81
27.09
5.13
Treynor Ratio
(3.42)
0.1552
0.7582
(8.42)
(0.02)
(0.03)
0.2129
10.17
(0.34)
(0.56)
Maximum Drawdown
37.65
509.71
247.8
131.09
29.72
41.78
26.33
107.58
58.58
78.36
Variance
38.03
3323.9
1159.11
322.49
44.72
33.71
38.41
184.99
105.69
95.97
Market Risk Adjusted Performance
(3.41)
0.1652
0.7682
(8.41)
(0.01)
(0.02)
0.2229
10.18
(0.33)
(0.55)
Risk Adjusted Performance
(0.05)
0.0949
(0.01)
0.0856
0.0057
4.0E-4
0.0239
0.0527
0.0675
0.0827
Skewness
1.2
7.56
2.7
4.94
0.0625
2.75
(0.60)
3.93
0.9879
6.49
Semi Deviation
N/A
9.48
N/A
8.74
N/A
N/A
6.79
6.57
6.53
3.07
Information Ratio
(0.10)
0.1091
(0.04)
0.0923
(0.02)
(0.03)
(0.0009)
0.0471
0.0637
0.0831
Value At Risk
(10.11)
(10.00)
(42.00)
(18.35)
(10.00)
(7.45)
(10.50)
(13.04)
(15.28)
(7.14)
Expected Short fall
N/A
(36.70)
N/A
(10.75)
N/A
N/A
(4.52)
(13.00)
(13.80)
(7.72)
Downside Deviation
N/A
14.57
N/A
10.43
N/A
N/A
7.04
9.28
9.61
5.01
Semi Variance
N/A
89.85
N/A
76.41
N/A
N/A
46.08
43.15
42.65
9.41

Mangoceuticals, Common Competition Performance Charts

Five steps to successful analysis of Mangoceuticals, Common Competition

Mangoceuticals, Common's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mangoceuticals, Common in relation to its competition. Mangoceuticals, Common's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Mangoceuticals, Common in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mangoceuticals, Common's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mangoceuticals, Common, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Mangoceuticals, Common position

In addition to having Mangoceuticals, Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Moderate Funds Thematic Idea Now

Moderate Funds
Moderate Funds Theme
Funds or Etfs that combine stocks, bonds and money market instruments to get modest capital appreciation over time. The Moderate Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Moderate Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Mangoceuticals, Stock Analysis

When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY